These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38488824)

  • 21. Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
    Chiarenza A; Manetti F; Petricci E; Ruat M; Naldini A; Taddei M; Carraro F
    PLoS One; 2016; 11(3):e0149919. PubMed ID: 26934052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
    Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
    Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel approaches to therapy in CML.
    Bhatia R
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):115-120. PubMed ID: 29222245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
    Shah M; Bhatia R
    Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.
    Massaro F; Colafigli G; Molica M; Breccia M
    Expert Rev Hematol; 2018 Apr; 11(4):301-306. PubMed ID: 29522367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
    Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
    Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells.
    Zhang H; Li S
    Protein Cell; 2013 Mar; 4(3):186-96. PubMed ID: 23483480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.
    Valent P; Sadovnik I; Ráčil Z; Herrmann H; Blatt K; Cerny-Reiterer S; Eisenwort G; Lion T; Holyoake T; Mayer J
    Eur J Clin Invest; 2014 Dec; 44(12):1239-45. PubMed ID: 25371066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
    Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
    Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
    Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
    Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
    Cheloni G; Tanturli M; Tusa I; Ho DeSouza N; Shan Y; Gozzini A; Mazurier F; Rovida E; Li S; Dello Sbarba P
    Blood; 2017 Aug; 130(5):655-665. PubMed ID: 28576876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The chronic myeloid leukemia stem cell: stemming the tide of persistence.
    Holyoake TL; Vetrie D
    Blood; 2017 Mar; 129(12):1595-1606. PubMed ID: 28159740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.
    Calabretta B; Salomoni P
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1(Suppl 1):54-9. PubMed ID: 21250825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
    Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
    Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
    Parting O; Langer S; Kuepper MK; Wessling C; Li S; Braunschweig T; Chatain N; Maié T; Costa IG; Crysandt M; Huber M; Brümmendorf TH; Koschmieder S; Schemionek M
    Leukemia; 2020 Oct; 34(10):2635-2647. PubMed ID: 32684632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia.
    Sun J; Hu R; Han M; Tan Y; Xie M; Gao S; Hu JF
    Int J Biol Sci; 2024; 20(1):175-181. PubMed ID: 38164178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.